首页> 外国专利> In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus-Like Particles

In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus-Like Particles

机译:体内激活抗原提呈细胞以增强由病毒样颗粒诱导的免疫反应

摘要

The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens.
机译:本发明涉及以下发现:使用诸如抗-CD40抗体或富含非甲基化的C和G的DNA寡聚体(CpGs)的物质刺激抗原呈递细胞(APC)活化,可以显着增强在接种后接种的T细胞的特异性反应。与抗原偶联,融合或以其他方式结合的重组病毒样颗粒(VLP)。虽然用融合了淋巴细胞性绒毛膜脑膜炎病毒的细胞毒性T细胞(CTL)表位的重组VLP进行疫苗接种仅诱导了低水平的溶细胞活性,并且没有诱导有效的抗病毒保护,但与抗CD40抗体或CpG一起注射的VLP却诱导了强大的CTL活性。全面的抗病毒保护。因此,通过抗原呈递细胞激活剂例如抗CD40抗体或CpGs刺激APC激活可以显示出有效的佐剂作用,以用于接种与抗原结合,融合或附着的VLP。

著录项

  • 公开/公告号US2018015160A1

    专利类型

  • 公开/公告日2018-01-18

    原文格式PDF

  • 申请/专利权人 KUROS BIOSCIENCES AG;

    申请/专利号US201715442196

  • 申请日2017-02-24

  • 分类号A61K39/29;A61K39/385;A61K39;A61K39/395;C12N7;C07K14/005;A61K39/12;A61K39/39;

  • 国家 US

  • 入库时间 2022-08-21 13:03:37

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号